autologous adipose-derived mesenchymal cells
/ Regeneris Medical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 20, 2020
Adipose Mesenchymal Cells for Abatement of SARS CoV-2 Respiratory Compromise in COVID-19 Disease
(clinicaltrials.gov)
- P1; N=20; Not yet recruiting; Sponsor: Regeneris Medical
New P1 trial • Genetic Disorders • Hematological Disorders • Hemophilia • Infectious Disease • Lung Cancer • Novel Coronavirus Disease • Oncology • Pneumonia • Pulmonary Disease • Respiratory Diseases • Solid Tumor • Thoracic Cancer
1 to 1
Of
1
Go to page
1